Monday, August 29, 2016
CardioCell stem cells ‘improve well-being’ of heart failure patients
After Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver–and over the weekend posted broadly positive data, but questions, and the need for more clinical data, remain.
The San Diego, CA-based biotech has published new, top-line data from the ESC Congress in Rome, Italy that used its allogeneic mesenchymal stem cells, delivered through an IV, to heart failure patients with non-ischemic cardiomyopathy. READ FULL ARTICLE